The estimated Net Worth of Yutaka Sakurada is at least $170 Thousand dollars as of 2 May 2005. Yutaka Sakurada owns over 63 units of Haemonetics stock worth over $170,040 and over the last 21 years Yutaka sold HAE stock worth over $0.
Yutaka has made over 2 trades of the Haemonetics stock since 2004, according to the Form 4 filled with the SEC. Most recently Yutaka bought 63 units of HAE stock worth $1,714 on 2 May 2005.
The largest trade Yutaka's ever made was buying 68 units of Haemonetics stock on 8 November 2004 worth over $1,632. On average, Yutaka trades about 44 units every 58 days since 2004. As of 2 May 2005 Yutaka still owns at least 2,347 units of Haemonetics stock.
You can see the complete history of Yutaka Sakurada stock trades at the bottom of the page.
Yutaka's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy, and Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: